Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond.
Identifieur interne : 000505 ( PubMed/Curation ); précédent : 000504; suivant : 000506Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond.
Auteurs : Sean Ekins [États-Unis] ; Thomas R. Lane [États-Unis] ; Peter B. Madrid [États-Unis]Source :
- Pharmaceutical research [ 1573-904X ] ; 2020.
Descripteurs français
- KwdFr :
- MESH :
- pharmacologie : Antiviraux, Tilorone.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- Animaux, Coronavirus du syndrome respiratoire du Moyen-Orient, Ebolavirus, Humains, Marburgvirus, Pandémies, Virus du chikungunya.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Betacoronavirus (drug effects), Chikungunya virus (drug effects), Coronavirus Infections (drug therapy), Ebolavirus (drug effects), Humans, Marburgvirus (drug effects), Middle East Respiratory Syndrome Coronavirus (drug effects), Pandemics, Pneumonia, Viral (drug therapy), Tilorone (pharmacology).
- MESH :
- chemical , pharmacology : Antiviral Agents, Tilorone.
- drug effects : Betacoronavirus, Chikungunya virus, Ebolavirus, Marburgvirus, Middle East Respiratory Syndrome Coronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Animals, Humans, Pandemics.
Abstract
For the last 50 years we have known of a broad-spectrum agent tilorone dihydrochloride (Tilorone). This is a small-molecule orally bioavailable drug that was originally discovered in the USA and is currently used clinically as an antiviral in Russia and the Ukraine. Over the years there have been numerous clinical and non-clinical reports of its broad spectrum of antiviral activity. More recently we have identified additional promising antiviral activities against Middle East Respiratory Syndrome, Chikungunya, Ebola and Marburg which highlights that this old drug may have other uses against new viruses. This may in turn inform the types of drugs that we need for virus outbreaks such as for the new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Tilorone has been long neglected by the west in many respects but it deserves further reassessment in light of current and future needs for broad-spectrum antivirals.
DOI: 10.1007/s11095-020-02799-8
PubMed: 32215760
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000505
Links to Exploration step
pubmed:32215760Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond.</title><author><name sortKey="Ekins, Sean" sort="Ekins, Sean" uniqKey="Ekins S" first="Sean" last="Ekins">Sean Ekins</name><affiliation wicri:level="1"><nlm:affiliation>Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC27606, USA. sean@collaborationspharma.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC27606</wicri:regionArea></affiliation></author><author><name sortKey="Lane, Thomas R" sort="Lane, Thomas R" uniqKey="Lane T" first="Thomas R" last="Lane">Thomas R. Lane</name><affiliation wicri:level="1"><nlm:affiliation>Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC27606, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC27606</wicri:regionArea></affiliation></author><author><name sortKey="Madrid, Peter B" sort="Madrid, Peter B" uniqKey="Madrid P" first="Peter B" last="Madrid">Peter B. Madrid</name><affiliation wicri:level="1"><nlm:affiliation>SRI International, 333 Ravenswood Avenue, Menlo Park, California, 94025, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>SRI International, 333 Ravenswood Avenue, Menlo Park, California, 94025</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32215760</idno><idno type="pmid">32215760</idno><idno type="doi">10.1007/s11095-020-02799-8</idno><idno type="wicri:Area/PubMed/Corpus">000505</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000505</idno><idno type="wicri:Area/PubMed/Curation">000505</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000505</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond.</title><author><name sortKey="Ekins, Sean" sort="Ekins, Sean" uniqKey="Ekins S" first="Sean" last="Ekins">Sean Ekins</name><affiliation wicri:level="1"><nlm:affiliation>Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC27606, USA. sean@collaborationspharma.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC27606</wicri:regionArea></affiliation></author><author><name sortKey="Lane, Thomas R" sort="Lane, Thomas R" uniqKey="Lane T" first="Thomas R" last="Lane">Thomas R. Lane</name><affiliation wicri:level="1"><nlm:affiliation>Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC27606, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC27606</wicri:regionArea></affiliation></author><author><name sortKey="Madrid, Peter B" sort="Madrid, Peter B" uniqKey="Madrid P" first="Peter B" last="Madrid">Peter B. Madrid</name><affiliation wicri:level="1"><nlm:affiliation>SRI International, 333 Ravenswood Avenue, Menlo Park, California, 94025, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>SRI International, 333 Ravenswood Avenue, Menlo Park, California, 94025</wicri:regionArea></affiliation></author></analytic><series><title level="j">Pharmaceutical research</title><idno type="eISSN">1573-904X</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Betacoronavirus (drug effects)</term><term>Chikungunya virus (drug effects)</term><term>Coronavirus Infections (drug therapy)</term><term>Ebolavirus (drug effects)</term><term>Humans</term><term>Marburgvirus (drug effects)</term><term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term><term>Pandemics</term><term>Pneumonia, Viral (drug therapy)</term><term>Tilorone (pharmacology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antiviraux (pharmacologie)</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient ()</term><term>Ebolavirus ()</term><term>Humains</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Marburgvirus ()</term><term>Pandémies</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Tilorone (pharmacologie)</term><term>Virus du chikungunya ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Tilorone</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term><term>Chikungunya virus</term><term>Ebolavirus</term><term>Marburgvirus</term><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term><term>Tilorone</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term><term>Ebolavirus</term><term>Humains</term><term>Marburgvirus</term><term>Pandémies</term><term>Virus du chikungunya</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">For the last 50 years we have known of a broad-spectrum agent tilorone dihydrochloride (Tilorone). This is a small-molecule orally bioavailable drug that was originally discovered in the USA and is currently used clinically as an antiviral in Russia and the Ukraine. Over the years there have been numerous clinical and non-clinical reports of its broad spectrum of antiviral activity. More recently we have identified additional promising antiviral activities against Middle East Respiratory Syndrome, Chikungunya, Ebola and Marburg which highlights that this old drug may have other uses against new viruses. This may in turn inform the types of drugs that we need for virus outbreaks such as for the new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Tilorone has been long neglected by the west in many respects but it deserves further reassessment in light of current and future needs for broad-spectrum antivirals.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32215760</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1573-904X</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>25</Day></PubDate></JournalIssue><Title>Pharmaceutical research</Title><ISOAbbreviation>Pharm. Res.</ISOAbbreviation></Journal><ArticleTitle>Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond.</ArticleTitle><Pagination><MedlinePgn>71</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11095-020-02799-8</ELocationID><Abstract><AbstractText>For the last 50 years we have known of a broad-spectrum agent tilorone dihydrochloride (Tilorone). This is a small-molecule orally bioavailable drug that was originally discovered in the USA and is currently used clinically as an antiviral in Russia and the Ukraine. Over the years there have been numerous clinical and non-clinical reports of its broad spectrum of antiviral activity. More recently we have identified additional promising antiviral activities against Middle East Respiratory Syndrome, Chikungunya, Ebola and Marburg which highlights that this old drug may have other uses against new viruses. This may in turn inform the types of drugs that we need for virus outbreaks such as for the new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Tilorone has been long neglected by the west in many respects but it deserves further reassessment in light of current and future needs for broad-spectrum antivirals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ekins</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC27606, USA. sean@collaborationspharma.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Thomas R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC27606, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madrid</LastName><ForeName>Peter B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>SRI International, 333 Ravenswood Avenue, Menlo Park, California, 94025, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21TR001718</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R44GM122196-02A1</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pharm Res</MedlineTA><NlmUniqueID>8406521</NlmUniqueID><ISSNLinking>0724-8741</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>O6W7VEW6KS</RegistryNumber><NameOfSubstance UI="D013994">Tilorone</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002646" MajorTopicYN="N">Chikungunya virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029043" MajorTopicYN="N">Ebolavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029024" MajorTopicYN="N">Marburgvirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013994" MajorTopicYN="N">Tilorone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral</Keyword><Keyword MajorTopicYN="N">broad spectrum</Keyword><Keyword MajorTopicYN="N">interferon inducers</Keyword><Keyword MajorTopicYN="N">respiratory virus infections</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>02</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32215760</ArticleId><ArticleId IdType="doi">10.1007/s11095-020-02799-8</ArticleId><ArticleId IdType="pii">10.1007/s11095-020-02799-8</ArticleId><ArticleId IdType="pmc">PMC7100484</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>PLoS Negl Trop Dis. 2019 Nov 21;13(11):e0007890</Citation><ArticleIdList><ArticleId IdType="pubmed">31751347</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell. 2010 Mar 19;140(6):805-20</Citation><ArticleIdList><ArticleId IdType="pubmed">20303872</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ann N Y Acad Sci. 2008 Dec;1147:383-94</Citation><ArticleIdList><ArticleId IdType="pubmed">19076458</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>ACS Infect Dis. 2015 Jul 10;1(7):317-26</Citation><ArticleIdList><ArticleId IdType="pubmed">27622822</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 1977 Jan;11(1):92-7</Citation><ArticleIdList><ArticleId IdType="pubmed">836018</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Zh Mikrobiol Epidemiol Immunobiol. 2001 Jul-Aug;(4):31-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11569258</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Acta Virol. 2001 Jun;45(3):181-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11774897</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Annu Rev Virol. 2019 Sep 29;6(1):435-458</Citation><ArticleIdList><ArticleId IdType="pubmed">31567063</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Viruses. 2019 Oct 18;11(10):</Citation><ArticleIdList><ArticleId IdType="pubmed">31635418</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Interferon Cytokine Res. 2001 Feb;21(2):65-73</Citation><ArticleIdList><ArticleId IdType="pubmed">11244570</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 2019 Apr 15;264:22-31</Citation><ArticleIdList><ArticleId IdType="pubmed">30794895</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 1976 Apr;31(1):125-9</Citation><ArticleIdList><ArticleId IdType="pubmed">177724</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Acta Virol. 1977 Mar;21(2):114-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17279</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 1976 Feb;9(2):233-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1267425</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2015 May;479-480:110-21</Citation><ArticleIdList><ArticleId IdType="pubmed">25749629</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vopr Virusol. 2004 Mar-Apr;49(2):8-11</Citation><ArticleIdList><ArticleId IdType="pubmed">15106376</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2013;8(4):e60579</Citation><ArticleIdList><ArticleId IdType="pubmed">23577127</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vopr Virusol. 1990 Sep-Oct;35(5):411-4</Citation><ArticleIdList><ArticleId IdType="pubmed">1702569</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Expert Rev Anti Infect Ther. 2017 May;15(5):483-492</Citation><ArticleIdList><ArticleId IdType="pubmed">28286997</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2020 Mar 5;382(10):929-936</Citation><ArticleIdList><ArticleId IdType="pubmed">32004427</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Acta Virol. 1979 Mar;23(2):153-8</Citation><ArticleIdList><ArticleId IdType="pubmed">39439</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 1970 Sep 18;169(3951):1214-5</Citation><ArticleIdList><ArticleId IdType="pubmed">4317924</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 1970 Sep 18;169(3951):1213-4</Citation><ArticleIdList><ArticleId IdType="pubmed">4317923</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2019 Oct 10;381(15):1444-1457</Citation><ArticleIdList><ArticleId IdType="pubmed">31597021</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Fiziol Zh. 2012;58(2):39-43</Citation><ArticleIdList><ArticleId IdType="pubmed">22873051</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2020 Mar 23;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32205350</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2018 Jan 25;62(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">29133569</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2019 May 29;93(12):</Citation><ArticleIdList><ArticleId IdType="pubmed">30918074</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Diagn Lab Immunol. 2002 Nov;9(6):1282-94</Citation><ArticleIdList><ArticleId IdType="pubmed">12414762</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>ACS Omega. 2019 Jan 31;4(1):2353-2361</Citation><ArticleIdList><ArticleId IdType="pubmed">30729228</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Soc Exp Biol Med. 1981 Feb;166(2):257-62</Citation><ArticleIdList><ArticleId IdType="pubmed">7225194</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell Rep. 2017 Jan 17;18(3):816-829</Citation><ArticleIdList><ArticleId IdType="pubmed">28099857</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antibiot Khimioter. 2001;46(10):14-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11881188</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 1976 Jan;9(1):189-95</Citation><ArticleIdList><ArticleId IdType="pubmed">176928</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Klin Med (Mosk). 2002;80(12):54-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12638414</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>F1000Res. 2015 Oct 20;4:1091</Citation><ArticleIdList><ArticleId IdType="pubmed">26834994</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell Mol Immunol. 2016 Jan;13(1):3-10</Citation><ArticleIdList><ArticleId IdType="pubmed">26189369</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Russ J Immunol. 2002 Jul;7(2):105-14</Citation><ArticleIdList><ArticleId IdType="pubmed">12687252</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2016 Jan 06;90(6):3086-92</Citation><ArticleIdList><ArticleId IdType="pubmed">26739045</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Molecules. 2015 Dec 02;20(12):21458-63</Citation><ArticleIdList><ArticleId IdType="pubmed">26633340</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Soc Exp Biol Med. 1971 May;137(1):357-60</Citation><ArticleIdList><ArticleId IdType="pubmed">5581674</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hoppe Seylers Z Physiol Chem. 1984 Aug;365(8):859-66</Citation><ArticleIdList><ArticleId IdType="pubmed">6489934</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2010 May;54(5):2017-22</Citation><ArticleIdList><ArticleId IdType="pubmed">20194696</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Zh Mikrobiol Epidemiol Immunobiol. 2001 May-Jun;(3):42-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11550558</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Pharmacol. 1995 May 11;49(9):1223-33</Citation><ArticleIdList><ArticleId IdType="pubmed">7763303</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2009 Sep 25;325(5948):1680-2</Citation><ArticleIdList><ArticleId IdType="pubmed">19779197</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000505 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000505 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:32215760
|texte= Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:32215760" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |